Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
DTG, RPV, DTG/RPV FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Refractory Breast Carcinoma
Interventions
Cyclophosphamide, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Pembrolizumab, Recombinant Interferon Alpha 2b-like Protein, Questionnaire Administration, Quality of Life Assessment
Drug · Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Completed No phase listed Observational Accepts healthy volunteers

Caretaker Hemodynamic Parameters Validation

NCT04685733
Conditions
Blood Pressure, Cardiac Output, Left Ventricular Ejection Time, Heart Rate Variability
Interventions
Non-invasive hemodynamic measurements
Device
Lead sponsor
CareTaker Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Not applicable Interventional Results available

Servo-Ventilation In-lab PSG Evaluation

NCT02808338
Conditions
Sleep Apnea Syndromes
Interventions
Philips BiPAP AutoSV Advanced System One, Modified Philips BiPAP ASV, ResMed S7 VPAP Adapt, ResMed S9 VPAP Adapt
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Completed Not applicable Interventional Results available

Complex Sleep Apnea Syndrome (CompSAS) Resolution Study

NCT00915499
Conditions
Complex Sleep Apnea Syndrome
Interventions
VPAP Adapt SV
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Phoenix, Arizona • Chicago, Illinois • Skokie, Illinois + 3 more
Conditions
Prostate Cancer
Interventions
LEAD RT, HEIGHT RT
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Miami, Florida
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Software Enhancements to the Respironics BiPAP autoSV Device Compared to BiPAP S/T Device

NCT01241604
Conditions
Sleep Disordered Breathing
Interventions
BiPAP S/T, BiPAP Auto SV3
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03698942
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Pre-Eclampsia
Interventions
Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
Interventions
Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
Conditions
Adverse Drug Interactions
Interventions
Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Interventions
Treatment Group: AGN1 LOEP SV Kit, Control Group: PMMA bone cement
Device
Lead sponsor
AgNovos Healthcare, LLC
Industry
Eligibility
50 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Mesa, Arizona • Orlando, Florida + 9 more
Conditions
Prostate Cancer
Interventions
Galeterone, Enzalutamide
Drug
Lead sponsor
LTN PHARMACEUTICALS, INC.
Industry
Eligibility
18 Years and older · Male only
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
51
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Conditions
Undifferentated Shock
Interventions
Starling SV
Device
Lead sponsor
Ivor Douglas
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Micro and Macro Circulation in Sepsis

NCT05694455
Conditions
Sepsis, Septic Shock
Interventions
Starling Stroke Volume (Starling SV)- Passive Leg Raise, Microscan Sublingual Microscopy, Venous Excess Ultrasound Scoring (VExUS), Urine Collection
Diagnostic Test · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Alcohol Intoxication, Sexual Violence, Helping Behavior
Interventions
RealConsent1.0, RealConsent2.0, Stress Management, Alcohol intoxication, No-Alcohol Placebo
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
21 Years to 25 Years
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Lincoln, Nebraska